CNCR Stock Overview
ETF Series Solutions - Range Cancer Therapeutics ETF is an exchange traded fund launched by ETF Series Solutions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
ETF Series Solutions - Range Cancer Therapeutics ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.21 |
52 Week High | US$17.96 |
52 Week Low | US$9.22 |
Beta | 0 |
1 Month Change | -11.63% |
3 Month Change | 4.18% |
1 Year Change | 11.28% |
3 Year Change | -54.25% |
5 Year Change | -30.62% |
Change since IPO | -51.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
CNCR | US Capital Markets | US Market | |
---|---|---|---|
7D | -3.1% | -0.7% | -3.2% |
1Y | 11.3% | 23.2% | 19.3% |
Return vs Industry: CNCR underperformed the US Capital Markets industry which returned 23.2% over the past year.
Return vs Market: CNCR underperformed the US Market which returned 19.3% over the past year.
Price Volatility
CNCR volatility | |
---|---|
CNCR Average Weekly Movement | 5.3% |
Capital Markets Industry Average Movement | 3.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNCR's share price has been volatile over the past 3 months.
Volatility Over Time: CNCR's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | n/a | loncarfunds.com/cncr |
ETF Series Solutions - Range Cancer Therapeutics ETF is an exchange traded fund launched by ETF Series Solutions. The fund is managed by Exchange Traded Concepts, LLC. It invests in public equity markets of the United States.
ETF Series Solutions - Range Cancer Therapeutics ETF Fundamentals Summary
CNCR fundamental statistics | |
---|---|
Market cap | US$20.33m |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CNCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CNCR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CNCR perform over the long term?
See historical performance and comparison